These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22467671)

  • 21. Exposure-response analyses of tigecycline tolerability in healthy subjects.
    Passarell J; Ludwig E; Liolios K; Meagher AK; Grasela TH; Babinchak T; Ellis-Grosse EJ
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):123-9. PubMed ID: 19748422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
    Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
    Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis.
    Cheong EY; Gottlieb T
    Med J Aust; 2011 Apr; 194(7):374-5. PubMed ID: 21470094
    [No Abstract]   [Full Text] [Related]  

  • 24. Patient-level data provide additional insight for tigecycline all-cause mortality meta-analysis.
    McGovern PC; Quintana A
    Clin Infect Dis; 2012 Dec; 55(12):1739-40; author reply 1740-1. PubMed ID: 22972861
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparative analysis between survivors and nonsurvivors patients treated with tigecycline.
    Curcio D
    Braz J Infect Dis; 2013; 17(2):277-8. PubMed ID: 23453414
    [No Abstract]   [Full Text] [Related]  

  • 26. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
    Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
    Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis.
    Verde PE; Curcio D
    Clin Infect Dis; 2012 Aug; 55(3):471-2. PubMed ID: 22511552
    [No Abstract]   [Full Text] [Related]  

  • 29. A Lesser Known Side Effect of Tigecycline: Hypofibrinogenemia.
    Yılmaz Duran F; Yıldırım H; Şen EM
    Turk J Haematol; 2018 Mar; 35(1):83-84. PubMed ID: 29212626
    [No Abstract]   [Full Text] [Related]  

  • 30. Tigecycline-induced acute pancreatitis: case report and literature review.
    Hung WY; Kogelman L; Volpe G; Iafrati M; Davidson L
    Int J Antimicrob Agents; 2009 Nov; 34(5):486-9. PubMed ID: 19540093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatitis in tigecycline Phase 3 and 4 clinical studies.
    McGovern PC; Wible M; Korth-Bradley JM; Quintana A
    J Antimicrob Chemother; 2014 Mar; 69(3):773-8. PubMed ID: 24216769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tigecycline-induced coagulopathy.
    McMahan J; Moenster RP
    Am J Health Syst Pharm; 2017 Feb; 74(3):130-134. PubMed ID: 28122754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of minocycline and tigecycline in a hamster model of leptospirosis.
    Tully CC; Hinkle MK; McCall S; Griffith ME; Murray CK; Hospenthal DR
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):366-9. PubMed ID: 22018938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tigecycline: Alone or in combination?
    Cai Y; Bai N; Liu X; Liang B; Wang J; Wang R
    Infect Dis (Lond); 2016 Jul; 48(7):491-502. PubMed ID: 26982103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tigecycline: benefits and risks.
    Cai Y; Wang R
    Lancet Infect Dis; 2011 Nov; 11(11):804-5. PubMed ID: 21784707
    [No Abstract]   [Full Text] [Related]  

  • 36. Tigecycline-induced inhibition of mitochondrial DNA translation may cause lethal mitochondrial dysfunction in humans.
    Vandecasteele SJ; Seneca S; Smet J; Reynders M; De Ceulaer J; Vanlander AV; van Coster R
    Clin Microbiol Infect; 2018 Apr; 24(4):431.e1-431.e3. PubMed ID: 28870729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of tigecycline: focus on use for approved indications.
    Vardakas KZ; Rafailidis PI; Falagas ME
    Clin Infect Dis; 2012 Jun; 54(11):1672-4. PubMed ID: 22431809
    [No Abstract]   [Full Text] [Related]  

  • 38. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.
    Chen Z; Shi X
    Medicine (Baltimore); 2018 Sep; 97(38):e12467. PubMed ID: 30235740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tigecycline-induced pancreatitis.
    Lipshitz J; Kruh J; Cheung P; Cassagnol M
    J Clin Gastroenterol; 2009 Jan; 43(1):93. PubMed ID: 18769361
    [No Abstract]   [Full Text] [Related]  

  • 40. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.
    Burkhardt O; Rauch K; Kaever V; Hadem J; Kielstein JT; Welte T
    Int J Antimicrob Agents; 2009 Jul; 34(1):101-2. PubMed ID: 19278835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.